Insmed Incorporated Company was founded in 1999 and is headquartered in Richmond, Virginia. Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company's primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X.

Formatech provides contract development services for pharmaceutical companies, including cell culture and fermentation, pre-formulation, dosage form, and purification development services. Its dosage forms include liquid, controlled release, tablets, capsules as well as topicals, such as gels, ointments, and creams. It also provides project management services to its contract development customers. The company also offers manufacturing services, such as aseptic fill, finishing, and lyophilization. Formatech's specializations include small molecules, vaccines, and monoclonal antibodies.

"Osme" means smell in Greek, and Osmetech is intent on finding ways to sniff out what's wrong with people. Founded in 1993, the company has several molecular diagnostics products on the market. Its eSensor system can detect RNA and DNA targets, such as genes that indicate sensitivity to certain drugs, as well as for detecting cystic fibrosis carriers. Though headquartered in the UK, the company's principal operations are in the US. Its diagnostic systems, tubes, and microarrays are used by hospitals, laboratories, and physician practices through its US sales force and a network of international distributors.

Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. Dyax Corp. (Dyax) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company uses the drug discovery technology, known as phage display, to identify antibody, small protein and peptide compounds for clinical development. The Company’s product DX-88 (ecallantide), is in late stage clinical trial development in two separate indications. In addition to DX-88, the phage display technology has allowed Dyax to develop a substantial pipeline of drug candidates. In June 2008, the Company completed a second phase three study, known as EDEMA4.

Green Foods Corporation company manufactures and sells nutritional products made from green barley grass and other natural ingredients. Of its lead products, its Green Magma provides healthy doses of vitamins, minerals, and antioxidants to promote overall wellness. Carrot Essence is beta-carotene and vitamin C supplement, and Magma Slim is a weight loss formula. Green Foods also makes products for pets, Barley Cat and Barley Dog. Dr. Yoshihide Hagiwara founded Green Foods Corporation, which sells its products throughout the US online and through brokers, in 1980.

CorMedix believes the way to a healthy heart is through the kidney -- and vice versa. The biopharmaceutical company develops medications for the treatment and prevention of cardiorenal disease (kidney and related cardiac dysfunctions), including a liquid and gel used to prevent infection and clotting which can occur during intravenous treatments, such as dialysis and chemotherapy. Also, in an agreement with Shiva Biomedical, the company is developing a new formulation of the drug deferipone, to be used in the prevention of kidney damage in high-risk patients. The company expects to market its products worldwide. CorMedix, controlled by a group of its officers, filed to go public in November 2009.

Goldshield Group plc, through its subsidiaries, engages in the development, marketing, and distribution of pharmaceutical and consumer health products. It offers ethical pharmaceuticals, non-prescription medicines, vitamins, minerals and supplements, and various other healthcare products. The company’s pharmaceutical products comprise Ostex, a glucosamine sulphate for joints; Flexeze for glucosamine; and Flexeze Truefil capsules for joints and connective tissues. Its pharmaceutical products are used for chronic disease areas, including cardiovascular diseases, central nervous system disorders, and musculoskeletal conditions. The company’s consumer health products include Appesat for natural weight loss; LIPObind, a natural weight management supplement; Lubramine, a supplement for joint health; Kamillosan, a breastfeeding product; and Infaderm, a soap-free bubble bath product. Its consumer health products also include joints and mobility, bone health, antioxidants, heart and circulation, digestion and detox, weight management, men’s health, women's health, skin care and beauty, heart and bone health, fitness nutrition, immune boosters, joint health, cardiac health, multi vitamins, pet health, centural specials, anti aging, eye health, and well being products. In addition, the company develops wellbeing villages and resorts; publishes magazines for consumers, as well as sells subscriptions and advertising space; and provides telemarketing and management services. Goldshield Group operates in the United Kingdom, Ireland, North America, and India. The company was founded in 1991 and is headquartered in Croydon, the United Kingdom. As of December 21, 2009, Goldshield Group plc was taken private.

International Brachytherapy (IBt) is planting the seeds of future health and vitality. IBt develops and markets interstitial implants -- commonly referred to as seeds -- used in brachytherapy to treat cancer. The radiotherapeutic implants are inserted inside or near cancerous tissue, delivering radioactive doses to tumors while sparing surrounding tissue. Founded in 1996, IBt operates from its Belgian headquarters as well as a US subsidiary, IBt Inc., and UK subsidiary IBt ltd. It also owns a majority stake in medical components provider Urorad GmbH.

The Quigley Corporation company was founded in 1989 and is headquartered in Doylestown, Pennsylvania. The Quigley Corporation is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products which comprise the Cold Remedy and Contract Manufacturing segments. The Company is also involved in the research and development of potential natural base health products, including, but not limited to, prescription medicines along with supplements and cosmeceuticals for human and veterinary use, which comprise the Ethical Pharmaceutical segment. Cold-Eeze is one of the Company’s primary cold remedy over the counter (OTC) products. The Cold Remedy segment, where Cold-Eeze is represented, is reviewed regularly to realize any new consumer opportunities in flavor, convenience and packaging to help improve market share for the Cold-Eeze product. The Company’s customers include a range of large wholesalers, mass merchandisers, and multi-outlet pharmacy chains.

Xanodyne Pharmaceuticals, Inc. company develops and manufactures drugs for pain management and women's health. Its commercial offerings include pain treatments Darvocet, Roxicodone, and Oramorph SR, as well as Duet prenatal vitamins. Zipsor, a treatment for mild to moderate inflammatory pain such as arthritic pain, and Lysteda, a treatment for menorrhagia (excessive menstrual bleeding), were both approved by the FDA in 2009. Xanodyne has several other drugs in development, including one for mild to moderate pain in late-stage clinical trials. The company funds its development efforts through sales of its commercial products, which are marketed through an internal sales force.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.